NasdaqGS:GRALBiotechs
GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions
GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of securities class action lawsuits.
See our latest analysis for GRAIL.
Since that disclosure and the resulting securities class actions, GRAIL’s share price has seen a 14.95% 1 month share price return and a 40.28% 3 month share price return. The 1 year total shareholder return is 53.73%, suggesting...